natgillin/translations-raw huggingface dataset:
The isolation system of clause 14, wherein said isolating washer is comprised of suitable metal core coated with a dielectric material. 
Izolacijski sustav prema zahtjevu 2, naznačen time, da se spomenuti izolacijski zaporni prsten (26) sastoji od prikladne metalne jezgre obložene dielektričnim materijalom.
The compound of formula (I) according to claim 6, and/or a pharmaceutically acceptable salt thereof, and/or solvates, racemic mixture, enantiomers, diasteromers, tautomers thereof, wherein Ar is phenyl or pyridyl, each of which is optionally substituted with one or more groups chosen from halo, —CN, and C1-6 haloalkyl. 
Spoj s formulom (I) prema bilo kojem od patentnih zahtjeva 1-4, i/ili njegova farmaceutski prihvatljiva sol, i/ili njegovi solvati, racemična smjesa, enantiomeri, dijasteromeri, tautomeri, naznačen time što R2 je C1-4 alkil, poželjno metil i etil; i/ili pri čemu R3 je H; i/ili pri čemu m je 1.
Run time: 30 minutes. 
Dužina trajanja: 30 minuta.
The method of claim 1, wherein the compound of Formula (Ia) has a structure selected from the group consisting of: 
Spoj prema zahtjevu 1 naznačen time što ima strukturu odabranu iz skupine koju čine:
the parameter B k,1 depends on the GOP/scene-complexity parameter S noI / I; and/or the parameter B k,2 depends on the GOP/scene-complexity parameter SblP. 
parametar Bk,1 ovisi o GOP/parametru složenosti scene SnoI/I; i/ili parametar Bk,2 ovisi o GOP/parametru složenosti scene Sb/P.
wherein X and m are as defined above, and R1c is alkyl which may be substituted by A, cycloalkyl which may be substituted by A, alkenyl which may be substituted by A, alkynyl which may be substituted by A, aryl or a heterocyclic group which may be substituted by alkyl, and the compound of the above formula (V); or 
(X) gdje su X i m kao što je definirano gore, R'" je alkil koji može biti supstituiran sa A, cikloalkil koji može biti supstituiran sa A, alkenil koji može biti supstituiran sa A, alkinil koji može biti supstituiran sa A, aril ili heterociklička skupina i spoj prema gornjoj formuli (V); ili
The compound of claim 1, where R2 is —OH and R3 is H. 
Spoj u skladu s patentnim zahtjevom 1, naznačen time, da je R* -OH i R? je H.
The angling lure of claim 1, wherein the free end of said attachment rod is curved to prevent said free end from digging into said body. 
Mamac za pecanje udicom sukladno bilo kojem od prethodnih zahtjeva, pri čemu je slobodni kraj (40) dodatne šipke (32) zakrivljen kako bi se spriječilo da se slobodni kraj (40) ukopa u tijelo (18).
In the boron “ate” complex of formula (XV), R3 and Y both are chloro. 
(1) u kompleksu borata formule (XV), i RŽ i Y su hloro;
A compound of the following formula Ia: in which 
Spoj sljedeće formule Ia:
a nucleic acid encoding a light chain variable region of the antibody or antigen binding fragment thereof of any one of claims 1 to 9 and a nucleic acid encoding a heavy chain variable region of the antibody or antigen binding fragment thereof of any one of claims 1 to 9, wherein each nucleic acid is on a separate vector or on the same vector; or 
(a) nukleinsku kiselinu koja kodira varijabilno područje lakog lanca humaniziranog protutijela ili njegovog fragmenta koji veže antigen u skladu s bilo kojim od zahtjeva 1 do 6 i nukleinsku kiselinu koja kodira varijabilno područje teškog lanca humaniziranog protutijela ili njegovog fragmenta koji veže antigen u skladu s bilo kojim od zahtjeva 1 do 6, pri čemu je svaka nukleinska kiselina na zasebnom vektoru ili na istom vektoru; ili
a sequence with at least 95 percent sequence identity to the full length of a DNA sequence selected from SEQ ID NOs:1-2 with promoter activity, 
sekvence sa najmanje 95 posto identičnosti sekvence sa punom dužinom DNK sekvence odabrane od SEQ ID BR.:1-2 sa promotorskom aktivnosti,
total number of subjects (N) 
(87) Broj međunarodne objave:
In one embodiment, the Fc-region comprises or consists of the amino acid sequence of SEQ ID NO: 62. 
Protutijelo ili fragment za vezanje antigena prema zahtjevu 4 naznačeno time da Fc-regija sadrži ili se sastoji od sekvence amino kiselina SEQ ID NO: 62.
According to another inventive aspect, as a result of the displacement of the actuation element there is released at least one previously defined flow passageway for the flow to enter inside the accumulation chamber. 
(52) za odgovarajuće ispuštanje protoka iz kapsule (1). Kapsula u skladu s patentnim zahtjevom 1 ili 2, naznačena time, da kao rezultat pomicanja elementa za pokretanje
m is 1, 2, 3, 4, or 5 when R1 is attached via a nitrogen atom, and m is 0, 1, 2, 3, 4, or 5 when R1 is attached via a carbon atom; n is 1, 2, for 3; 
m predstavlja 1, 2, 3, 4 ili 5 kada je R1 vezan preko atoma dušika, a m predstavlja 0, 1, 2, 3, 4 ili 5 kada je R1 vezan preko atoma ugljika; n predstavlja 1, 2 ili 3;
is a cleavable protecting group. 
R* je nukleofugalna grupa;
Aspect: Method according to one of the preceding aspects, wherein the mobile communication technology is one out of the following: 
Postupak prema jednom od prethodnih zahtjeva, pri čemu je mobilna komunikacijska tehnologija jedna od slijedećih:
Microaggregation of IL-2 at a concentration of 1 mg/ml is substantially absent when SDS is present at higher than about 500µg/mg, and so it is typical to add SDS to give a final SDS concentration of at least 500µg SDS per mg of IL-2 (e.g. 
Mikroagregacija IL-2 pri koncentraciji od 1 mg/ml u biti izostane kada je SDS prisutan pri više od oko 500ug/mg, i tako je tipično da se doda SDS da dade konačnu koncentraciju SDS od barem 500ug SDS po mg IL-2 (na pr.
Such signal emitting means could be adapted to emit electromagnetic signals and/or magnetic fields. 
Takvo sredstvo koje emitira signal može se prilagoditi da emitira elektromagnetske signale i/ili magnetska polja.
a VH sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO:115 and/or a VL sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO:114; 
(d) VH sekvencu koja ima najmanje 95% identiteta sekvence od aminokiselinske sekvence SEQ ID NO: 115i VL sekvencu koja ima najmanje 95% identiteta sekvence od aminokiselinske sekvence SEQ ID NO: 114;
(c)a stable karyotype for at least 10, preferably, 20 cell passages, 
stabilni kariotip kroz najmanje 10, poželjno 20, pasaža stanica,
A pharmaceutical composition comprising a tumour associated peptide according to Claim 1 or 2, a nucleic acid according to Claim 4 or an expression vector according to Claim 5 and a pharmaceutically acceptable carrier, preferably in the form of a cancer vaccine, optionally comprising at least one suitable adjuvant. 
Farmaceutski sastav koji obuhvaća tumoru pridruženi peptid prema bilo kojem od Zahtjeva 1 do 3, nukleinsku kiselinu prema Zahtjevu 4 ili 5 ili vektor ekspresije prema Zahtjevu 6 te Tarmaceutski prikladan nosač, poželjno u obliku cjepiva protiv raka, a po izboru može sadržavati barem jedan prikladan adjuvans.
The residue was stirred with methanol (1.5 I) for 16 hours and the resulting solid collected, washed twice with methanol, dried, and recrystallised from methanol to give the title compound (78 g), m.p. 
Ostatak se miješa s metanolom (1,5 1) tijekom 16 sati 1 dobivena čvrsta supstanca se sakupi, ispere se dva puta s metanolom, suši se i rekristalizira iz metanola tako da se dobiva naslovni spoj (78 g)t.t.
is H, halogen, perhaloalkyl, CN, SR5, NHR5, N(R5)2, aryl, or heteroaryl, wherein said aryl is optionally substituted with up to two substituents selected from C1-8 alkyl, halogen, perhalo alkyl, and alkoxy, and said heteroaryl is optionally substituted with up to two substituents selected from halogen and C1-8 alkyl; 
je H, halogen, perhaloalkil, CN, SR5, NHR5, N(R5)2, aril ili heteroaril pri čemu je navedeni aril po izboru supstituiran sve do sa po dva supstituenda izabrana iz skupine koju čine C1-8alkil, halogen, perhalo alkil i alkoksi te je navedeni heteroaril po izboru supstituiran sve do sa po dva supstituenda izabrana iz skupine koju čine halogen i C1-8alkil;
and R20 are each independently selected from halo, hydroxy, cyano, nitro, carboxyl; 
R*iR? su svaki nezavisno odabrani od halo, hidroksi, cijano, nitro, karboksila; polihaloC, salkila, polihaloC;.galkiloksi,;
Such systems are particularly advantageous in the frame of the present invention since using such systems allows efficient circulation of rinsing solutions through the packed bed external column. 
Takvi sustavi su posebno preporučljivi unutar okvira ovoga izuma jer uporaba takvoga sustava omogućava učinkovitu cirkulaciju otopine za ispiranje kroz vanjsku kolonu s nabijenim zrncima.
trimming of the veneer in longitudinal direction 
podrezivanje furnira u uzdužnom smjeru 74
allowing the yeast to convert at least a portion of the water soluble glucose and xylose in the second conversion medium to at least a second propagated yeast and a second portion of the fermentation product in a second conversion step having a second sugar-to-cells conversion ratio which is less than the first sugar-to-cells conversion ratio, wherein the second sugar-to-cells conversion ratio is a percent weight ratio of the water soluble glucose and xylose converted to the propagated yeast in the second conversion step to totally converted water soluble glucose and xylose in the second conversion medium, on a carbon basis. 
puštanja da kvasac pretvara u najmanju ruku dio u vodi topljive glukoze i ksiloze u drugom pretvorbenom mediju u najmanju ruku drugi trazmnoženi kvasac i drugi dio produkta vrenja u drugom koraku pretvorbe kojeg se provodi u drugom vremenu koje je dulje od vremena prve pretvorbe i ima drugi pretvorbeni omjer između šećera i stanica koji je manji od prvog pretvorbenog omjera između šećera i stanica, gdje je drugi pretvorbeni omjer između šećera i stanica postotni težinski omjer u vodi topljive glukoze i ksiloze pretvorene u trazmnoženi kvasac u drugom koraku pretvorbe i posve pretvorene u vodi topljive glukoze i ksiloze u drugom pretvorbenom mediju, na bazi ugljika.
For example, as shown in Figure 26, a compound of Formula 9 (which may be formed as described above with respect to Figure 19) may be protected as a 7,9-acetal linked analog of Formula 21 (where R1=R2=Ph; P1=TBDMS; R7=CH3; R8=R9=H in generalized formula O of Scheme 6). 
Na primjer, kao što je prikazano na slici 26, spoj formule 9 (koji može biti izveden kao što je gore opisano u odnosu na sliku 19) može biti zaštićen kao 7,9-acetalno povezani analog formule 21 (gdje R=R>=Ph; P,=TBDMS; Rg=CH;i Rg=R.o=H u općoj formuli O iz sheme 6).
represents a hydrogen atom, an optionally substituted C1-6 alkyl group, an optionally substituted C3-8 cycloalkyl group or an optionally substituted C1-6 alkoxy group; 
predstavlja atom vodika, po izboru supstituiranu C1-6 alkil skupinu, po izboru supstituiranu C3-8 cikloalkil skupinu ili po izboru supstituiranu C1-6 alkoksi skupinu;
a Fab fragment comprising wild-type CH1 and CL domains of an immunoglobulin; a mutated Fab fragment (a) of claim 1; 
Fab fragment divljeg tipa koji se sastoji od CH1 i CL domena divljeg tipa imunoglobulina te VH i VL domena antitijela koje prepoznaje epitope od interesa, te
for compounds of formula I wherein A represents S, W represents -C(O)-[CRxRy]p-, reaction of a compound of formula III as hereinbefore defined, with a compound of formula VI, L4-W2-D VI wherein L4 is a suitable leaving group or -OH, W2 represents -C(O)-[CRxRy]p-, and D is as defined in Claim 1; 
za spojeve s formulom I pri čemu A predstavlja S, W predstavlja -C(O)-[CRxRy]p-, reakcijom spoja s formulom III kao što je definirano u daljnjem tekstu, sa spojem s formulom VI, -W2-D VI pri čemu L4 je prikladna izlazna skupina ili -OH, W2 predstavlja -C(O)-[CRxRy]p-, i D je kako je definirano u zahtjevu 1;
wherein R represents H or trimethylsilyl, R2 is as defined in formula (I) and R3 represents H or a suitable protecting group; with an aryl halide or triflate of formula (VI) wherein R1 is as defined in formula (I) and X represents halide or triflate; and optionally thereafter forming a pharmaceutically acceptable salt thereof. 
n=R R £ o (XI) gdje R predstavlja H ili trimetilsilil, R* je kako je definirano u formuli (1), a R* predstavlja H ili prikladnu zaštitnu grupu; sa aril halidom ili triflatom formule (VI)
The used compound is selected from compounds having the following formula: wherein a, b and c respectively denote, independently from each other, a single bond or a double bond, with the proviso that at least one of a, b and c represents a double bond, and with the proviso that if a is single bond and b is double bond R2 is not H; 
PATENTNI ZAHTJEVI Spoj izabran između spojeva koji imaju sljedeću formulu: gdje a, bi c odgovarajuće označavaju, nezavisno jedan od drugoga, jednostruku vezu ili dvostruku vezu, uz uvjet da barem jedan od a, b i c predstavlja dvostruku vezu, i uz uvjet da ako je a jednostruka veza i b je dvostruka veza, tada R2 nije H;
The invention is a method to form three-dimensional image inside transparent stone (1) and it is characterized in that it comprises process steps of 
PATENTNI ZAHTJEVI Postupak formiranja trodimenzionalne slike unutar transparentnog kamena (1) koji obuhvaća sljedeće korake procesa:
A method for preparing a formula (I) compound according to any one of claims 1 to 9 where R4 represents a -CH2R4b group with R4b representing a phenyl or phenyl-methyl group substituted by one group chosen from among OH and NR9R10 groups, comprising a reductive amination reaction between a compound of following formula (VIII): 
heterociklil ili heterociklil-(C;-C;)alkilnu skupinu koja može biti supstituirana s jednom ili više skupina odabranih od (C;-Cs)alkil, OH te NRpR;3 skupina, s tim da Ri2 i Ria jesu kao što je definirano u patentnom zahtjevu 1, obuhvaća reakciju reduktivnog aminiranja između spoja sljedeće formule (VIII):
A method for processing broadcasting data in a receiver, the method comprising: receiving a broadcast signal comprising a signal frame, wherein the signal frame comprises preamble symbols including constellation values corresponding to Layer 1 signaling data, referred to as L1 signaling data, and an Layer 1 header, wherein, the preamble symbols Layer 1 are divided into blocks and each Layer 1 block has 3408 subcarriers, and wherein the Layer 1 header includes Layer 1 time interbearing mode information, referred to as L1 TI mode information, that indicates a time interleaving depth and L1_INFO_SIZE information that indicates the half size of the L1 signaling data and Layer 1 block padding data; 
Metoda za obradu emitiranog podatka u prijamniku, metoda obuhvaća: prihvaćanje emitiranog signala koji obuhvaća okvir signala, pri čemu okvir signala obuhvaća simbole početnog niza uključujući konstelacijske vrijednosti koje odgovaraju signalnom podatku razine 1, naznačenom kao signalni podatak L1, 1 zaglavlje razine 1, pri čemu su simboli početnog niza razine 1 podijeljeni u blokove i svaki blok razine 1 ima 3408 podnosača, i pri čemu zaglavlje razine1l uključuje informaciju vrste umetanja vremena razine 1,
After that, cells were treated with 800 uM of peroxynitrite for an overnight. 
Nakon toga, stanice su obrađene preko noći s 800 uM peroksinitrita.
These starter cultures should be able to ferment the fibre composition and to reduce the pH by the production of acids. 
Te će starter-kulture moći fermentirati i sastavinu vlakana, čime će se, zahvaljujući proizvodnji kiseline, sniziti pH.
A method of production of cold rolled Fe-Si steel sheet according to claim 1 wherein the sulfur content is lower than 0.010%. 
Postupak proizvodnje hladno valjanog Fe-S1 čeličnog lima prema zahtjevu 1 naznačen time da je sadržaj sumpora manji od 0.010%.
Use of a compound represented by the formula (I) wherein R1 is as defined in claim 1, or a salt thereof, in combination with an insulin sensitizer, for manufacture of an agent for the prophylaxis or treatment of diseases in which insulin resistance is involved. 
BD N f Ck gF9-R! (I) gdje R! je kao definiran u zahtjevu 1, ili njegova sol, u kombinaciji s pojačivačem osjetljivosti na inzulin, za proizvodnju sredstva za profilaksu ili liječenje oboljenja u kojima je sadržana inzulinska rezistencija.
Commercially available tetrabenazine is a racemic mixture of the RR and SS isomers and it would appear that the RR and SS isomers (hereinafter referred to individually or collectively as trans -tetrabenazine because the hydrogen atoms at the 3 and 11b positions have a trans relative orientation) are the most thermodynamically stable isomers. 
Komercijalno raspoloživ tetrabenazin je racemična smjesa RR 1 SS izomera i pokazati će se da su RR 1 SS izomeri (kasnije označeni pojedinačno ili skupno kao trans-tetrabenazini stoga što vodikovi atomi u položajima 3 i 11b imaju trans-relativnu orijentaciju) termodinamički najstabilniji izomeri.
The present invention is directed to meeting this need, and provides a method directed to the prevention and/or treatment of abstinence syndrome in opioid dependent pregnant women and their fetuses. 
Ovaj izum je usmjeren na udovoljavanje toj potrebi, te pruža metodu usmjerenu na sprječavanje i/ili liječenje apstinencijskog sindroma kod o opioidima ovisnih trudnih žena i njihovih fetusa.
Pure fractions were concentrated and extracted with CH2Cl2. 
Čiste frakcije su koncentrirane i ekstrahirane sa CHCb.
In some embodiments, haloalkyl is a “C1-4 haloalkyl” and the group contains 1 to 4 carbons, some embodiments contain 1 to 3 carbons, some embodiments contain 1 to 2 carbons, some embodiments contain I carbon. 
U nekim oblicima, haloalkil je "C,.4 haloalkil" i grupa sadrži 1 do 4 ugljikova atoma, neki oblici sadrže 1 do 3 ugljikova atoma, naki oblici sadrže 2 do 2 ugljika, a neki sadrže 1 ugljik.
an antibody comprising a heavy chain comprising the amino acid sequence of SEQ ID NO: 229 and a light chain comprising the amino acid sequence of SEQ ID NO: 238; 
(5) protutijelo koje sadržava teški lanac koji sadržava aminokiselinski slijed SEQ ID NO: 229 (H46) i laki lanac koji sadržava aminokiselinski slijed SEQ ID NO: 238 (L17) (H46L17);
Another preferred embodiment of the present invention is the compound of Formula (I) wherein R1 is (C1-C6)alkyl, (C3-C7)cycloalkyl, or tetrahydrofuranyl; and R2 is hydrogen or to methyl; or a pharmaceutically acceptable salt thereof. 
Spoj u skladu s patentnim zahtjevom 1, naznačen time što je R' (C,-Cs)alkil, (C3-Cy)cikloalkil ili tetrahidrofuranil; a R" je vodik ili metil; ili njegova farmaceutski prihvatljiva sol.
A cell of the Enterococcus gallinarum strain deposited under accession number NCIMB 42488, or a derivative thereof. 
Stanica ili biološki čista kultura soja Enterococcus gallinarum naznačena time da je deponirana pod pristupnim brojem NCIMB 42488.
binding of the solubilising agent to an anion exchange resin material by mixing the G-CSF solution with the suspended resin material and removal of the resin material by filtration; 
vezanja sredstva za solubiliziranje na anionskoizmjenjivački smolni materijal miješanjem otopine G-CSF sa suspendiranim smolnim materijalom i uklanjanja smolnog materijala filtriranjem;
Analyses of the crystals following micronization revealed the presence of a second polymorph (orthorhombic form L) in addition to the known monoclinic form in the starting material. 
Analize kristala nakon mikronizacije otkrile su dodatnu prisutnost sekundarnih polimorfa (ortoromskog oblika L) uz poznate monoklinske oblike u početnom materijalu.
The compound of any of claims 1-13 or the composition of claim 14 for use in a method of treating a cancer deficient in Homologous Recombination (HR) dependent DNA double strand break (DSB) repair pathway. 
Spoj ili pripravak za primjenu prema zahtjevima od 12 do 16, naznačen time, što je rak deficitaran u pogledu puta popravka dvostrukog lančanog loma (DBS) DNK ovisnog o homolognoj rekombinaciji (HR).
The system of claim 1, further comprising a gasification system for converting the asphaltenes stream to a synthesis gas. 
Sustav u skladu s patentnim zahtjevom 21, naznačen time, da nadalje obuhvaća sustav uplinjavanja za konverziju struje asfaltena u sintezni plin.
A seed of the plant of any one of claims 1-4 or 6, wherein said seed is treated with an AHAS-inhibiting imidazolinone herbicide, or a mixture of an imidazolinone herbicide, a sulfonylurea herbicide, and/or a triazolopyrimidine herbicide. 
Sjeme biljke prema bilo kojem od zahtjeva 1 do 4 ili 6, naznačeno time, da se spomenuto sjeme tretira sa AHAS-inhibirajućim imidazolinon-herbicidom, ili mješavinom imidazolinon-herbicida, sulfonilurea-herbicida i/ili triazolopirimidin-herbicida.
A method for preparing a pharmaceutical composition comprising the steps of: 
Postupak pripreme farmaceutskog pripravka koji obuhvaća korake:
the CDR-L3 comprises the amino acid sequence of SEQ ID NO: 119 or a variant thereof, wherein the variant comprises one or two amino acid substitutions. The composition of claim 11, wherein the antibody or antigen-binding fragment thereof comprises a VH region comprising an amino acid sequence at least 90% identical to SEQ ID NO: 20 and a VL region comprising an amino acid sequence that is at least 90% identical to SEQ ID NO: 22 of antibody NI-203.26C11. The composition of claim 11, wherein the antibody or antigen-binding fragment thereof comprises in its variable region: 
(viii) VHCDR1: položaji 26-37 od SEQ ID NO: 20, VHCDR2: položaji 52-67 SEQ ID N0: 20, VHCDR3: položaji 100-110 od SEQ ID NO: 20, VKCDR1: položaji 24-38 od SEQ ID NO: 22, VKCDR2: položaji 54-60 od SEQ ID NO: 22, i VKCDR3: pozicije 93-101 od SEQ ID NO: 22, ili, pri čemu jedna ili više CDR može sadržavati jednu ili dvije supstitucije aminokiselina. Antitijelo ili njegov IAPP / proIAPP vezujući fragment u skladu s patentnim zahtjevom 1, naznačeno time, da sadržava u svojoj varijabilnoj regiji
Ulipristal acetate or a metabolite thereof is particularly efficient to reduce or stop bleeding in a patient afflicted with uterine fibroids, or to reduce the size of uterine fibroids. 
Ulipristal acetat, 1li bilo koji metabolit izabran iz grupe koja obuhvaća CDB-3877, CDB-3963, CDB-3236, i CDB- 4183 za uporabu radi smanjenja ili zaustavljanja krvarenja u bolesnice koja boluje od uterinih fibroida prema zahtjevu 1 pri čemu se primjenjuje u obliku tablete.
m is an integer from 0 to 6; 
m je cijeli broj od 0 do 6;
A method for increasing plaque size of a viral culture comprising, administering to a host cell culture infected with a virus, a composition comprising one or more ethylene oxide propylene oxide (EO-PO) block copolymers, wherein the EO-PO block copolymers comprise poloxamer 407 (Pluronic F127), poloxamer 403 (Pluronic P123) or a combination thereof, wherein the concentration of EO-PO block copolymer is about 0.001 % to about 3.0 % (w/v), and wherein the composition increases viral plaque size compared to a control viral culture without administering one or more EO-PO copolymers. 
Metoda za povećanje veličine pločice kulture virusa sadrži, primjenjujući na stanicu kulture domaćina inficiranu virusom, spoj koji sadrži jedan ili više etilen-oksid-propilen-oksid (EO-PO) blok kopolimera, gdje EO-PO blok kopolimera sadrži poloksamer 407 (pluronski F127), poloksamer 403 (pluronski P123) ili njihovu kombinaciju, gdje je koncentracija EO-PO bloka kopolimera od otprilike 0,001 % do otprilike 3,0 % (m/V) 1 gdje spoj povećava veličinu pločice kulture virusa u usporedbi s kontroliranom kulturom virusa bez primjene jednog ili više EO-PO kopolimera.
attaching a second tag with an affinity to a second capture element to said target molecule in the aptamer-target affinity complex; 
priključivanje druge oznake s afinitetom za drugi zahvatni element na navedenu ciljanu molekulu u afinitetnom kompleksu aptamer-cilj;